Success Metrics

Active Trials
1(25%)

Phase Distribution

Ph phase_2
1
25%
Ph not_applicable
2
50%
Ph phase_1
1
25%

Phase Distribution

1

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
1(25.0%)
N/ANon-phased studies
2(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

4

all time

Status Distribution
Active(2)
Other(2)

Detailed Status

unknown2
Recruiting1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
1
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Phase 11 (25.0%)
Phase 21 (25.0%)
N/A2 (50.0%)

Trials by Status

recruiting125%
not_yet_recruiting125%
unknown250%

Recent Activity

1 active trials
Showing 4 of 4
not_yet_recruitingphase_1

Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial

NCT07485569
recruitingnot_applicable

Patient-centered Personalized Cardiac Rehabilitation in Post Acute Coronary Syndrome (BREAK-trial)

NCT07038265
unknownnot_applicable

Development of Diagnostics and Treatment of Urological Cancers

NCT02994758
unknownphase_2

Personalised Therapy for Metastatic ADPC Determined by Genetic Testing and Avatar Model Generation

NCT02795650

Clinical Trials (4)

Showing 4 of 4 trials
NCT07485569Phase 1

Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial

Not Yet Recruiting
NCT07038265Not Applicable

Patient-centered Personalized Cardiac Rehabilitation in Post Acute Coronary Syndrome (BREAK-trial)

Recruiting
NCT02994758Not Applicable

Development of Diagnostics and Treatment of Urological Cancers

Unknown
NCT02795650Phase 2

Personalised Therapy for Metastatic ADPC Determined by Genetic Testing and Avatar Model Generation

Unknown

All 4 trials loaded

Drug Details

Intervention Type
COMBINATION PRODUCT
Total Trials
4